Net profit for the third quarter rose to Rs 633 crore from Rs 525 crore a year ago. Analysts on average expected a profit of Rs 629 crore, according to Thomson Reuters I/B/E/S.
Lupin, the world's seventh-largest generic drugs maker, said its sales in North America, which accounts for more than 45 percent of the company's overall revenue, rose nearly 58 percent in the quarter. The company launched four products in the United States over the three months ended December.
Shares of the company were up about 1 percent at 2:18 pm in Mumbai, while the broader index was almost unchanged.
Get Breaking news, live coverage, and Latest News from India and around the world on NDTV.com. Catch all the Live TV action on NDTV 24x7 and NDTV India. Like us on Facebook or follow us on Twitter and Instagram for latest news and live news updates.